Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
One trial showed improved peak walking times and decreased pain
Research Note: A 1998 study in The Journal of Immunology by Malinda et al
Do you have any ideas or suggestions
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
& Peng, L
Bartke, A., Sun, L., Fang, Y
US$ 23.15
US$ 25.57
US$ 23.97
US$ 26.20
US$ 26.78
US$ 22.66
US$ 28.53
US$ 29.01
US$ 22.46
US$ 26.30
